Novartis Considers Sale of Select Radiopharmaceutical Assets from Advanced Accelerator Applications-VCBeat

On October 3, Seeking Alpha cited a Bloomberg report that Novartis plans to divest part of the assets of its radiopharmaceuticals unit, Advanced Accelerator Applications (AAA).

However, the report also indicated that Novartis’ plan to sell part of AAA's assets is still in the preliminary stage, and the final outcome might be no sale at all.

In recent years,NovartisHua relies on "buying" to build upFinishedThe radioligand therapy platform has gradually become global.The leader in the radioligand therapy field.Currently, NovartisTwo major radioactive therapeutic products have been launched, including Lutathera (177Lu-dotatate) and Pluvicto (177Lu-PSMA-617).

This Novartis plan to spin offThe radiopharmaceutical assets come from AAA, a company that wasAcquired by Novartis for $3.9 billion in October 2017Under one's command. In addition, the acquisition of AAA also allowed Novartis to obtain itsMain products Lutathera and technology platform, further expansionFinishedOncology Product Pipeline.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank you for your companionship and we look forward to your feedback.

Scan the QR code to provide valuable suggestions